HOUSTON, April 23, 2025 /PRNewswire/ — Milagro, a leading provider of autonomous medical coding solutions, is pleased to announce its expanded partnership with Tampa General Hospital (TGH), which has yielded significant improvements in the hospital’s surgical coding and reimbursement processes.
TGH is Milagro’s first customer to go live with its advanced AI-powered coding platform and you can now find Milagro in Connection Hub on Epic Showroom.
Milagro has defined an implementation process with TGH that sets the foundation for future deployments, broadening access to Milagro’s innovative, automated solution that tackles critical healthcare finance challenges.
Key achievements of the TGH and Milagro partnership include:
This successful partnership stemmed from ongoing communication and a shared vision between Milagro and TGH to leverage AI for enhanced efficiency in healthcare.
Milagro’s AI-driven technology, seamlessly integrated into existing workflows allows healthcare organizations to:
Milagro remains dedicated to developing solutions that help healthcare providers maximize revenue while enhancing their operational performance.
About Milagro
Established in 2020 by a team of leading medical data experts, Milagro is dedicated to simplifying medical coding and streamlining coding operations. Milagro is leading the change in autonomous medical coding with cutting-edge technology that automates coding processes.
For more information about Milagro, please visit www.milagroai.com
Epic is a registered trademark of Epic Systems Corporation
Contact: meet@milagroai.com
Photo: https://healthtechnologynet.com/wp-content/uploads/2025/04/Milagro.jpg
Logo: https://healthtechnologynet.com/wp-content/uploads/2025/04/Milagro_Logo.jpg
SOURCE Milagro
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…